2026年上半年财报季收官,中国创新药产业交出了一份分水岭式的答卷。行业正在告别“烧钱讲故事”的阶段,走向“赚钱才是硬道理”的价值兑现期。 这种转变并非行业普遍现象,而是由商业化放量、出海授权爆发、资金来源多元化三重力量共同推动的分化。在这一过程中,一个困扰创新药行业多年的产业命题正在愈发清晰:从研发投入到商业回报的价值闭环,是否已经被真正打通? 谈及上半年产业宏观变化,上海市卫生和健康发展...
Source Link2026年上半年财报季收官,中国创新药产业交出了一份分水岭式的答卷。行业正在告别“烧钱讲故事”的阶段,走向“赚钱才是硬道理”的价值兑现期。 这种转变并非行业普遍现象,而是由商业化放量、出海授权爆发、资金来源多元化三重力量共同推动的分化。在这一过程中,一个困扰创新药行业多年的产业命题正在愈发清晰:从研发投入到商业回报的价值闭环,是否已经被真正打通? 谈及上半年产业宏观变化,上海市卫生和健康发展...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.